KR20230130610A - 치료적 방사성 표지된 접합체 및 요법에서의 이의 용도 - Google Patents

치료적 방사성 표지된 접합체 및 요법에서의 이의 용도 Download PDF

Info

Publication number
KR20230130610A
KR20230130610A KR1020237015744A KR20237015744A KR20230130610A KR 20230130610 A KR20230130610 A KR 20230130610A KR 1020237015744 A KR1020237015744 A KR 1020237015744A KR 20237015744 A KR20237015744 A KR 20237015744A KR 20230130610 A KR20230130610 A KR 20230130610A
Authority
KR
South Korea
Prior art keywords
compound
compound according
gsao
formula
nodaga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015744A
Other languages
English (en)
Korean (ko)
Inventor
필립 호그
숀 이반 호
Original Assignee
센테너리 인스티튜트 오브 캔서 메디신 앤드 셀 바이올로지
더 유니버시티 오브 시드니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903727A external-priority patent/AU2020903727A0/en
Application filed by 센테너리 인스티튜트 오브 캔서 메디신 앤드 셀 바이올로지, 더 유니버시티 오브 시드니 filed Critical 센테너리 인스티튜트 오브 캔서 메디신 앤드 셀 바이올로지
Publication of KR20230130610A publication Critical patent/KR20230130610A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237015744A 2020-10-14 2021-10-14 치료적 방사성 표지된 접합체 및 요법에서의 이의 용도 Pending KR20230130610A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903727 2020-10-14
AU2020903727A AU2020903727A0 (en) 2020-10-14 Conjugates and their use in therapy
PCT/AU2021/051203 WO2022077068A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Publications (1)

Publication Number Publication Date
KR20230130610A true KR20230130610A (ko) 2023-09-12

Family

ID=81207378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015744A Pending KR20230130610A (ko) 2020-10-14 2021-10-14 치료적 방사성 표지된 접합체 및 요법에서의 이의 용도

Country Status (10)

Country Link
US (1) US20230398240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228710A4 (cg-RX-API-DMAC7.html)
JP (1) JP7890301B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130610A (cg-RX-API-DMAC7.html)
CN (1) CN116472068A (cg-RX-API-DMAC7.html)
AU (1) AU2021359638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195410A1 (cg-RX-API-DMAC7.html)
IL (1) IL302033A (cg-RX-API-DMAC7.html)
MX (1) MX2023004327A (cg-RX-API-DMAC7.html)
WO (1) WO2022077068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152229A1 (en) 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents
US20250269072A1 (en) * 2021-10-14 2025-08-28 Centenary Institute Of Cancer Medicine And Cell Biology Processes for preparing radiolabelled conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
WO2016088116A1 (en) * 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
LT3275883T (lt) 2015-03-25 2021-08-25 Fujifilm Corporation Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
US20220152229A1 (en) * 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents

Also Published As

Publication number Publication date
CN116472068A (zh) 2023-07-21
JP7890301B2 (ja) 2026-07-14
IL302033A (en) 2023-06-01
US20230398240A1 (en) 2023-12-14
MX2023004327A (es) 2023-08-30
CA3195410A1 (en) 2022-04-21
EP4228710A4 (en) 2025-04-09
EP4228710A1 (en) 2023-08-23
WO2022077068A1 (en) 2022-04-21
JP2023547954A (ja) 2023-11-14
AU2021359638A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7376481B2 (ja) 鉛またはトリウム放射性核種に連結されたpsma標的化化合物を含む錯体
AU2009200201B2 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US12296030B2 (en) Conjugates and their use as imaging agents
US20230398240A1 (en) Therapeutic radiolabelled conjugates and their use in therapy
US9050378B2 (en) N2S2 chelate-targeting ligand conjugates
JP2023523226A (ja) Psma結合リガンドを放射標識するための方法及びそのキット
KR20250044688A (ko) 표적화된 분자 영상화를 위한 구리의 방사성 제약 조성물
KR20090014164A (ko) 세포 영상화 및 치료를 위한 조성물 및 방법
US20250269072A1 (en) Processes for preparing radiolabelled conjugates
KR20250140611A (ko) 교모세포종의 치료 방법
KR20250109190A (ko) 암의 식별 및/또는 치료
AU2022374887A1 (en) Combination therapy of radionuclide complex
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902